Adjuvanticity of stealth liposornes on the immunogenicity of synthetic gp41 epitope of HIV-1

被引:15
作者
Singh, Sanjay K. [1 ]
Bisen, Prakash S. [1 ]
机构
[1] Bundelkhand Univ, Dept Biotechnol, JC Bose Inst Life Sci, Jhansi 284218, Uttar Pradesh, India
关键词
immunodominant epitope; immunogenecity; antibodies; HI; CMI; macrophagges; adjuvants; stealth liposomes; mPEG; mPEGSC; EDC; PE;
D O I
10.1016/j.vaccine.2006.02.047
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Present study aims to enhance the efficacy of liposomes as an adjuvant by steric protection and strengthen the path of vaccine research. PEG grafted liposomes carrying epitopes on their surface showed enhanced adjuvanticity than liposomes carrying epitopes for elicitation and prolongation of immune response to an antigenic epitope of gp41, a transmembrane protein of HIV-1. The multiples of epitope were incorporated onto the surface of liposomes by conjugating them with phosphatidylethanolamine that was used in the formulation of liposomes at an optimized ratio. Furthermore, the liposomes carrying epitopes on their surface were sterically protected by shielding with methoxypoly(ethylene glycol), mass 20 kDa. Methoxy-poly(ethylene glycol) was activated to its electrophilic N-succinimide carbonate derivative, methoxy-poly(ethylene glycol)-N-succinimide carbonate, that formed a urethane linkage with the amino group of phosphatidylethanolamine. The epitope was covalently coupled to phosphatidylethanolamine through an amide bond between the -COOH group of the epitope and -NH2 group of phosphatidylethanolamine under the catalysis of 1-ethyl-3-(3-dimethylaminopropy-1)-carbodiimide. PEG grafted epitopes carrying liposomes showed about two times higher immune response and prolonged persistence of antibodies than that of liposomes carrying epitopes without PEG moieties. (c) 2006 Published by Elsevier Ltd.
引用
收藏
页码:4161 / 4166
页数:6
相关论文
共 50 条
  • [21] Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer
    Nkolola, Joseph P.
    Cheung, Ann
    Perry, James R.
    Carter, Darrick
    Reed, Steve
    Schuitemaker, Hanneke
    Pau, Maria Grazia
    Seaman, Michael S.
    Chen, Bing
    Barouch, Dan H.
    VACCINE, 2014, 32 (18) : 2109 - 2116
  • [22] Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides
    Mohan, Teena
    Verma, Priyanka
    Rao, D. N.
    IMMUNOBIOLOGY, 2014, 219 (04) : 292 - 301
  • [23] Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41
    Clerici, M
    Barassi, C
    Devito, C
    Pastori, C
    Piconi, S
    Trabattoni, D
    Longhi, R
    Hinkula, J
    Broliden, K
    Lopalco, L
    AIDS, 2002, 16 (13) : 1731 - 1741
  • [24] Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer
    Reardon, Patrick N.
    Sage, Harvey
    Dennison, S. Moses
    Martin, Jeffrey W.
    Donald, Bruce R.
    Alam, S. Munir
    Haynes, Barton F.
    Spicer, Leonard D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (04) : 1391 - 1396
  • [25] Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
    Julg, Boris
    Stephenson, Kathryn E.
    Tomaka, Frank
    Walsh, Stephen R.
    Tan, C. Sabrina
    Lavreys, Ludo
    Sarnecki, Michal
    Ansel, Jessica L.
    Kanjilal, Diane G.
    Jaegle, Kate
    Speidel, Tessa
    Nkolola, Joseph P.
    Borducchi, Erica N.
    Braams, Esmee
    Pattacini, Laura
    Burgess, Eleanor
    Ilan, Shlomi
    Bartsch, Yannic
    Yanosick, Katherine E.
    Seaman, Michael S.
    Stieh, Daniel J.
    van Duijn, Janine
    Willems, Wouter
    Robb, Merlin L.
    Michael, Nelson L.
    Walker, Bruce D.
    Pau, Maria Grazia
    Schuitemaker, Hanneke
    Barouch, Dan H.
    NPJ VACCINES, 2024, 9 (01)
  • [26] Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41
    Burrer, R
    Haessig-Einius, S
    Aubertin, AM
    Moog, C
    VIROLOGY, 2005, 333 (01) : 102 - 113
  • [27] Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner
    Musich, Thomas
    Li, Liuzhe
    Liu, Lily
    Zolla-Pazner, Susan
    Robert-Guroff, Marjorie
    Gorny, Miroslaw K.
    JOURNAL OF VIROLOGY, 2017, 91 (08)
  • [28] Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection
    Vaidya, Naveen K.
    Ribeiro, Ruy M.
    Liu, Pinghuang
    Haynes, Barton F.
    Tomaras, Georgia D.
    Perelson, Alan S.
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [29] Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120
    Lekkerkerker, AN
    Ludwig, IS
    van Vliet, SJ
    van Kooyk, Y
    Geijtenbeek, TBH
    VIROLOGY, 2004, 329 (02) : 465 - 476
  • [30] ANTIBODIES TO A PUTATIVE HIV GP41 IMMUNOSUPPRESSIVE PEPTIDE, PHIVIS (583-599), DO NOT CORRELATE SIGNIFICANTLY WITH OUTCOME IN HIV-INFECTION
    CHEINGSONGPOPOV, R
    PANAGIOTIDI, C
    CAUN, K
    KLASSE, PJ
    PIPKORN, R
    BLOMBERG, J
    WEBER, J
    AIDS, 1990, 4 (03) : 251 - 253